Focused On-demand Library for Myelin regulatory factor

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Myelin gene regulatory factor

Alternative UPACC:

Q9Y2G1; O43582; Q9P1Q6


The Myelin Regulatory Factor, known alternatively as Myelin Gene Regulatory Factor, plays a pivotal role in the central nervous system's (CNS) myelination process. It functions as a precursor to a transcription factor essential for activating CNS myelin genes, such as MBP, MOG, MAG, DUSP15, and PLP1, during oligodendrocyte maturation. This protein's activity is crucial not only for oligodendrocyte differentiation but also for maintaining a mature, viable oligodendrocyte phenotype.

Therapeutic significance:

The Myelin Regulatory Factor is implicated in diseases like Encephalitis/encephalopathy, mild, with reversible myelin vacuolization (MMERV) and Cardiac-urogenital syndrome. Understanding its role could lead to novel therapeutic strategies for these conditions, emphasizing the importance of targeted research in uncovering potential treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.